MTSR - NASDAQ
Metsera, Inc.
$70.50
+0.0000%Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity. The company was incorporated in 2022 and is headquartered in New York, New York.
At a Glance
Live SnapshotMetsera, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Weak cash conversion. Significant portion of earnings not converting to cash—review working capital trends and capital intensity.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Cash Flow Quality Insight
Deteriorating cash generation: Both declining FCF and weak conversion rate signal fundamental challenges. Investigate margin pressure, rising costs, or working capital issues.
Metsera, Inc. Cash Flow Statement
MTSR • NASDAQ
| Metsera, Inc. Cash Flow Statement | Dec 2024 | Dec 2023 |
|---|---|---|
OPERATING ACTIVITIES | ||
-209.1M | -47.2M | |
14K | 2K | |
-9.3M | 0.0 | |
0.0 | 85K | |
92.9M | 7.7M | |
25.7M | 4M | |
-99.8M | -35.4M | |
INVESTING ACTIVITIES | ||
-43K | -29K | |
(0.0) | -28.2M | |
-43K | -28.2M | |
FINANCING ACTIVITIES | ||
397.2M | 0.0 | |
-252K | 0.0 | |
-19M | -217K | |
377.9M | 123.7M | |
CASH FLOW SUMMARY | ||
-864K | 167K | |
277.3M | 60.2M | |
75.2M | 15M | |
352.4M | 75.2M | |
-99.8M | -35.4M |
SEC Filings
MTSR - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2025 N/A | November 13, 2025 | November 12, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 12, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 10, 2025 | November 07, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 06, 2025 | November 03, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 04, 2025 | November 03, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 03, 2025 | November 03, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 03, 2025 | October 31, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 30, 2025 | October 29, 2025 | 2025 | |
8-K 8-K 2025 N/A | September 29, 2025 | September 29, 2025 | 2025 | |
8-K 8-K 2025 N/A | September 22, 2025 | September 21, 2025 | 2025 |
Related Guides
Continue your MTSR research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.